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Abstract 
Introduction: Obesity is treatment-resistant, and is linked with a number of serious, chronic diseases. Adult obe-
sity rates in the United States have tripled since the early 1960s. Recent reviews show that an increased ratio of 
omega-6 to omega-3 fatty acids contributes to obesity rates by increasing levels of the endocannabinoid signals 
AEA and 2-AG, overstimulating CB1R and leading to increased caloric intake, reduced metabolic rates, and weight 
gain. Cannabis, or THC, also stimulates CB1R and increases caloric intake during acute exposures. 
Goals: To establish the relationship between Cannabis use and body mass index, and to provide a theoretical 
explanation for this relationship. 
Results: The present meta-analysis reveals significantly reduced body mass index and rates of obesity in Cannabis 
users, in conjunction with increased caloric intake. 
Theoretical explanation: We provide for the first time a causative explanation for this paradox, in which rapid 
and long-lasting downregulation of CB1R following acute Cannabis consumption reduces energy storage and 
increases metabolic rates, thus reversing the impact on body mass index of elevated dietary omega-6/omega-
3 ratios.  
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Introduction 
The current review and meta-analysis establishes the 
impact of Cannabis use on body mass index (BMI) 
and obesity rates, and provides a well-supported phys-
iological, causative explanation for this impact. Canna-
bis use appears to reverse the impact of the modern 
American diet on health by reducing the effects of an 
elevated ratio of omega-6/omega-3 fatty acids on endo-
cannabinoid (eCB) tone. It is therefore necessary to un-
derstand how diet impacts health to understand the 
health impact of Cannabis use. 
Diet is the main cause of premature death and dis-
ability in the United States. The  modern  western diet is  
proinflammatory and obesogenic.1,2 Diseases associated 
with inflammation and obesity include cancer, cardiovas-
cular disease, diabetes mellitus (DM), Alzheimer’s dis-
ease, mood disorders, autoimmune disorders, liver and 
kidney disease, and musculoskeletal disabilities.1–12 
A significant dietary factor contributing to these health 
problems is an increased ratio of omega-6 (linoleic 
acid, LA) to omega-3 (a-linolenic acid, ALA) fatty 
acids,2,10,13–21 especially in the context of a high glyce-
mic load and reduced physical activity. 
Recent reviews show that dysregulation of the eCB 
system plays a major role in development of obesity 
and metabolic disorders, and strongly implicate the 
elevated omega-6/omega-3 ratio as a primary cause of 
this dysregulation.15,18,19,22–29 Omega-6 fatty acids are 
precursors of the eCBs N-arachidonoylethanolamide 
(AEA, or anandamide) and 2-arachidonoylglycerol (2-
AG). These eCB signals act via receptors, including 
CB1R and  CB2R, and CB1R plays a primary role in energy 
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homeostasis. An elevated dietary omega-6/omega-3 ratio 
therefore leads to elevated levels of AEA and 2-AG, over-
stimulation of CB1R, and dysregulation of energy homeo-
stasis leading to weight gain.21–23,25,29–32 
Metabolic consequences of the modern western diet 
Among the defining features of the modern western 
diet are a superabundance of calories from sugars and re-
fined starches leading to increased glycemic load, and a 
strongly elevated ratio of omega-6 to omega-3 polyun-
saturated fatty acids. The dietary omega-6/omega-3 
ratio in hunter-gatherers is estimated to be around 1:1 
to 3:1, whereas the ratio in the modern western diet is 
2,13,16,18,19 This shift in dietary as high as 20:1 or more. 
fatty acids increased sharply as more vegetable oils (espe-
cially soybean oil) and grains were incorporated into the 
diet. Corresponding with these changes in diet, rates of 
obesity and metabolic syndrome are increasing rapidly.14 
Obesity is a major health concern, strongly associ-
ated with systemic inflammation and metabolic syn-
drome, with increased risk of DM, a variety of 
cancer types, cardiovascular disease, autoimmune dis-
orders, anxiety, depression, Alzheimer’s disease, and 
other serious medical conditions.3,7,8,11,18,33–36 Dietary 
dysregulation of the eCB system is emerging as a pri-
mary cause of these conditions, suggesting that thera-
peutic interventions targeting this system should be 
investigated as a primary way to reduce or eliminate 
many of the most serious chronic diseases characteristic 
of modern western societies. 
Overview of the eCB system 
The eCB system is a signaling system with a prominent 
role in homeostasis, and is reviewed extensively else-
where.15,22,23,25,26,28,37 This signaling system occurs 
within the central nervous system (CNS) and in multi-
ple peripheral organs. 
The eCB system involves signals and receptors. The 
main signals are AEA and 2-AG. A major biosynthetic 
pathway for each begins with the omega-6 fatty acid 
(FA), LA, and proceeds through arachidonic acid. 
From arachidonic acid, multiple pathways and en-
zymes lead to AEA and 2-AG. AEA and 2-AG act 
through multiple receptors. Best-known are CB1R 
and CB2R, G protein-coupled receptors that are located 
in the CNS, as well as peripherally on a variety of or-
gans and tissues, including the gut, liver, bones, skeletal 
muscle, and adipose tissues. The eCB signals AEA and 
2-AG are degraded by enzymes, primarily fatty acid 
amine hydrolase for AEA and other fatty acid ethano-
lamides, and monoacylglycerol lipase for 2-AG and 
other monoacylglycerols.15,22,23,25,26,37–40 
Impact of the dietary omega-6/omega-3 ratio 
on the eCB system 
Recent reviews suggest that disruption of the eCB sys-
tem by an elevated omega-6/omega-3 ratio contributes 
strongly to the metabolic dysregulation associated with 
the modern western diet.15,18,19,22–30,41,42 Elevated pro-
duction of the eCBs AEA and 2-AG is central to the 
health problems associated with the elevated omega-6/ 
omega-3 ratio. Omega-6 FAs are converted to the 
eCB signals AEA and 2-AG. Therefore, the elevated 
omega-6/omega-3 ratio results in increased synthesis 
of AEA and 2-AG, resulting in overstimulation of 
CB1R (Fig. 1). Elevated CB1R activity in turn directly 
causes excess intake, storage, and conservation of en-
ergy leading to disruption of body mass and adipose 
tissue homeostasis.10,18,19,22,23,25,28–32,41–46 
Omega-3 fatty acids are receiving considerable at-
tention as dietary supplements due to their apparent 
ability to reduce obesity, inflammation, and associated 
chronic diseases. Their actions, at least in part, stem 
from their competition with omega-6 fatty acids for 
shared enzymes (elongases and D desaturases, 
which are limiting), leading to reduced AEA and 
2-AG levels and CB1R activity. Because of this com-
petition, it is the ratio between the two groups of 
fatty acids rather than the absolute amount that is 
key for energy homeostasis.4,10,12,15,17–22,47–50 
Role of eCB and CB1R in obesity 
and metabolic disorders 
CB1R is a primary mediator of energy uptake, storage, 
and conservation. It acts to maximize energy uptake 
and conservation through multiple mechanisms. Stim-
ulation of CB1R modulates taste and smell pathways to 
increase the palatability of food. It stimulates the ap-
petite centers of the brain, leading to hyperphagia 
and favoring fat accumulation in adipose tissue. At the 
same time, peripheral eCBs play a major role in regulat-
ing appetite, are influenced by the western diet, and AEA 
reduces energy expenditures, including energy expendi-
tures during sleep.10,18,22,23,25,28,29,31,32,39,43–46,51–53 . 
These actions contribute to homeostasis in the con-
text of a hunter-gatherer diet of plants, plant-feeding 
animals, and fish. However, the modern industrial 
western diet, characterized by an elevated omega-6/ 
omega-3 ratio,16 leads to chronic overstimulation of 
CB1R.
19,22,23 When combined with the elevated 
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FIG. 1. The impact of the modern western diet on the endocannabinoid system. (A) In the presence 
of a natural omega-6/omega-3 ratio, production of the endocannabinoid signals AEA and 2-AG and resulting 
stimulation of CB1R are compatible with a healthy BMI. (B) The modern western diet, with its elevated 
omega-6/omega-3 ratio, leads to excess production of AEA and 2-AG. This overstimulates CB1R, leading 
to weight gain and metabolic dysregulation. Modified from Freitas et al. (22). AEA, anandamide; 
N-arachidonoylethanolamide; 2-AG, 2-arachidonoylglycerol; BMI, body mass index. 
glycemic load of the modern western diet, this contrib-
utes strongly to increased rates of obesity, unfavorable 
lipid profiles, insulin resistance, exacerbation of inflam-
mation in the liver and kidneys, and increased cardio-
metabolic risk.10,29,42,54,55 
The critical role of CB1R in accumulation of en-
ergy reserves and BMI homeostasis is revealed in stud-
ies using CB1R antagonists, including rimonabant, as 
well as the peripherally restricted CB1R antagonists  
URB447 and AM6545. In laboratory and clinical trials, 
rimonabant was successful at reducing weight, but severe 
psychiatric side effects, including dizziness, anxiety, de-
pression, and nausea, caused discontinuation of clinical 
trials.55,56 
A therapeutic approach that acts both peripherally 
and centrally on the eCB system but does not cause se-
vere psychiatric side effects is of great interest. Periph-
erally restricted CB1R antagonists such as URB447 and 
AM6545 are showing promise, as peripheral eCB sig-
naling via CB1R plays a key role in stimulation of hy-
perphagia and dietary fat intake in the context of the 
western diet.45,46 These trials highlight the importance 
of the eCB system as a target of interest in weight con-
trol strategies.43–46,51,55,56 
The present study summarizes the data on Cannabis 
use, caloric intake, and BMI, establishing conclusively 
that Cannabis use is associated with reduced BMI and 
obesity rates, despite increased caloric intake. It then 
provides a theoretical, causative explanation for this par-
adox. This theory encompasses the causative role in obe-
sity of dietary disruption of the eCB system by an 
elevated omega-6/omega-3 fatty acid ratio. Cannabis 
Clark, et al.; Cannabis and Cannabinoid Research 2018, 3.1 262 
http://online.liebertpub.com/doi/10.1089/can.2018.0045 
(or THC) results in downregulation of CB1R, leading to 
reduced sensitivity to AEA and 2-AG, leading to signif-
icant health benefits in the context of this diet. 
Methods 
Data on the BMI of Cannabis users and nonusers, or 
studies reporting adjusted odds ratios (AORs) for Can-
nabis users being obese or overweight, were obtained 
from the literature. Studies addressing the health im-
pact of Cannabis use were identified using database 
searches and citation lists. Studies addressing the impact 
of therapeutic Cannabis use by cancer or AIDS patients 
or other patients, as a means to increase appetite and ca-
loric intake, were eliminated. Studies in which Cannabis 
was provided to nonusers over a several day period were 
rejected because short-term weight gain can be caused 
by water retention from increased sodium intake rather 
than accumulation of tissue mass. One study57 focused 
on imaging of CB1R was rejected due to low sample 
size (N = 10 users and N = 10 nonusers). 
The remaining data were compiled into a spread-
sheet. Paired t-tests were used to compare BMI of 
users and nonusers and were followed by determina-
tion of effect size (Hedges g with bias correction).58 
For rates of obesity, the mean and 95% confidence in-
tervals of AOR data, v 2 test for heterogeneity, and ef-
fect size determination using Hedges g were used to 
compare nonusers with users. When different usage 
rates were reported, data from the highest dosage 
group were used in the analysis. The mean across all 
usage groups, relative to nonusers, is also reported. 
Caloric intake data from short-term experimental stud-
ies were eliminated to ensure that subjects had reached 
a steady state. 
Results 
BMI data 
Nine studies were included that reported BMI of users 
and nonusers and met selection criteria (Table 1), and 
an additional two studies were identified that reported 
lower BMI in Cannabis users, but did not provide nu-
merical data. Of these studies, all reported lower values 
of BMI in Cannabis users, and only one of these did not 
reach statistical significance. A second study did not 
Table 1. Published Values of Body Mass Index for Cannabis Users and Nonusers 
Current user, 
Reference Nonuser Usage pattern Current user highest dosage p-Value or 95% CI 
72a 28.6 (335) 26.8 26.8 (451) <0.001 
110 24.4 (23,705) (women) 23 23 (6504) <0.05 
25.4 (14,324) (men) 24.3 24.3 (7474) <0.05 
59 28.22 (265) <0.05 (joint years)<0.009 
< 5 years 26.8 (552) (dependence) 
5–10 years 27.1 (42) 
10–15 years 26.6 (44) 
15+ years 25.5 (37) 25.5 (37) 
60 28 (6667) 
1–4 · /month 24.8 (557) <0.001 
> 5 · /month 24.1 (326) 24.1 (326) <0.001 
86 29.1 (2103) 27.2 (579) 27.2 (579) <0.0001 
70 28.9 (2252) Not significantly different 
< 180 days 28.5 (610) 
180–1799 days 28.7 (601) 
71b 26.6 (9771) 
> 1800 days 28.0 (154) 28 (154) 
1–4 · /month 25 (541) 
5–10 · /month 26.1 (135) 
11 · + /month 24.7 (176) 24.7 (176) <0.0001 
78 27 (28) 24 (30) 24 (30) <0.05 
87 29.1 (2861) 26.9 (831) 26.9 (831) <0.0001 
62 
61 
Numerical data not provided; user BMI < nonuser 
Numerical data not provided; lower BMI groups contain more Cannabis users, R250.96 
Not provided 
<0.02 
Mean 27.5 (N560,059) 26.0 25.5 (N518,272) <0.0005 
Statistically significant differences between Cannabis users and nonusers are indicated with bold font. 
aAdjusted for age (continuous), gender, small communities (yes/no), more than or equal to secondary school (yes/no), income level (<$20,000, 
>$20,000, do not know/refuse to answer), marital status (single, married/common law, separated/divorced/widowed), 3.5 h/week of leisure physical 
activity (yes/no), smoking status (never/former/current smoker with 1–14 cig./day, 15–24 cig./day, 25 cig./day), ever drink alcohol (yes/no/do not know 
or refuse to answer), total energy intake (kcal/day). 
bEffect remained after adjustment for age, gender, education, cigarette smoking, and caloric intake ( p = 0.003). 
BMI, body mass index. 
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report statistical analysis of the BMI data. Of those 
studies reporting significant negative correlations, two 
reported that longer duration of Cannabis use was as-
sociated with reduced BMI.59,60 
Across all studies reporting BMI, the overall mean 
BMI of nonusers was 27.5 kg/m2, while that of users 
(including data for all usage groups) was 26.0 kg/m2 
(Table 1). Limiting the analysis to the data from the 
highest dosage or duration of use reported in each 
study resulted in a mean BMI of users of 25.5 kg/m2, 
a difference of 2 kg/m2 that is significantly lower 
than the BMI of nonusers ( p < 0.001, paired t-test, 
T = 6.00, Fig. 2 and Table 2). The effect size of Canna-
bis use on BMI is large (Hedges g with bias 
correction =1.16)58 and the magnitude of the dif-
ference in BMI of users and nonusers is of clinical sig-
nificance. Thus, on average, nonusers in these studies 
are overweight, whereas Cannabis users are signifi-
cantly leaner and are near the healthy BMI range 
(18.5–25 kg/m2). 
Further support for reduced BMI in Cannabis users 
comes from the study by Warren et al.61 Although 
Warren et al.61 did not report BMI values, they grouped 
obese patients by BMI. The percent of each group that 
consumed Cannabis was negatively and linearly related 
FIG. 2. A comparison of BMI (kg/m2) of  
Cannabis users and nonusers. Data from current 
user, highest dosage presented in Table 1. 
Available data show that nonusers are 
overweight on average, whereas the mean BMI 
of users is not different from the upper limit of 
the healthy weight range. Data are expressed as 
mean – SEM (N = 12 data points from 11 studies, 
p < 0.001; Hedges g statistic =1.16). 
Table 2. Published Values for Adjusted Odds Ratios 
for Cannabis Users Being Obese and/or Overweight 
Reference Usage category OR users 95% CI p 
111a 
NESARC, 1 + · /year, <1 · /month 0.70 0.63–1.05 <0.001 
N = 41,633 
1 · /month–2 · /week 0.84 0.62–1.01 
Daily 0.61 0.46–0.82 
NCS-R, 1 + · /year, <1 · /month 0.7 0.44–1.11 <0.001 
N = 9103 
1 · /month–2 · /week 0.84 0.54–1.31 
Daily 0.73 0.43–1.23 
72b Past year 0.56 0.37–0.84 <0.05 
63c 1 · in last month 0.8 0.5–1.2 
N = 2566 Every few days 0.5 0.3–0.8 <0.01 
Daily 0.2 0.1–0.4 <0.001 
88d 0.42 0.13–1.36 
65e High vs. low use 0.2 <0.01 
N = 5141 Sporadic vs. low use 0.1 <0.01 
Increasing vs low 1.6 <0.05 
112f Male, past year 
N = 40,364 Overweight 0.88 0.67–1.16 
Obese 0.84 0.6–1.16 
Female, past year 
Overweight 0.88 0.53–1.45 
Obese 0.81 0.48–1.38 
Mean and 0.68 0.53–0.84 <0.05 
summary CI 
Statistically significant differences between Cannabis users and non-
users are indicated with bold font. Only one data point shows AOR >1. 
Hedges g statistic =1.07. 
aData from two databases, NESARC, National Epidemiologic Survey on 
Alcohol and Related Conditions (2001–2002); NCS-R, National Comorbid-
ity Survey–Replication (2001–2003). Adjusted for sex, age, race/ethnicity, 
educational level, marital status, region, and tobacco smoking status. 
Prevalence of obesity significantly lower in Cannabis users in both data 
sets ( p < 0.001).
bAge-standardized. 
cOdds ratio for BMI ‡25. Adjusted for participant’s gender and age, 
mother’s age and education, participant’s cigarette smoking, alcohol 
consumption, anxiety/depression and aggression/delinquency, partici-
pants BMI at 14 years. 
dRegular user, OR for abdominal obesity. Adjusted for age, gender, ed-
ucation, participation in at least moderate physical activity, weekly alco-
hol use, income to poverty ratio, having health insurance, marital status, 
other illicit drug use and having had rehabilitation. 
eControlled for adolescent obesity status, gender, ethnicity, and aver-
age family income.
fControlled for age, level of education, race/ethnicity, income, marital 
status, region of country, urban vs. rural residence, and lifetime and past 
year DSM-IV diagnoses of any mood disorder, any anxiety disorder, any 
personality disorder, any alcohol use disorder, and nicotine dependence. 
AOR, adjusted odds ratio; DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition. 
to the BMI of the group (R2 = 0.96). Danielsson et al.62 
also reported decreased rates of being overweight 
(BMI >24.9) in Cannabis users, but did not provide 
numerical data for BMI of the two groups. Thus, of 
11 studies reporting data on the relationship between 
Cannabis use and BMI, 9 showed a significant nega-
tive relationship between Cannabis use and BMI 
while the remaining 2 either reported lower BMI val-
ues in Cannabis users than nonusers that did not 
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reach statistical significance, or failed to provide sta-
tistical analyses (Table 1). 
Of course, decreased BMI in Cannabis users could 
result from activities correlated with Cannabis use, 
rather than Cannabis use itself. Two of the BMI stud-
ies adjusted for potential confounders, and significant 
differences remained following adjustment (Table 1). 
Six studies were identified that reported AORs of 
Cannabis users being obese or overweight (Table 2). 
Hayatbakhsh et al.63 followed a cohort of patients 
from birth until age 21 and found that subjects who 
used Cannabis showed a strongly reduced incidence 
of being overweight or obese relative to nonusers. A 
fully adjusted model that included BMI at age 14 
yielded an AOR of 0.2 for daily users being overweight 
(95% CI = 0.1–0.4). BMI was inversely correlated with 
the frequency of Cannabis use, lending support for cau-
sation.63 
Waterreus et al.64 found that a significantly lower 
percentage of users than nonusers were obese (53.7% 
of nonusers, 36.7% of occasional users, and 28.7% of 
frequent users were obese; p < 0.001). 
Huang et al.65 studied three categories of adolescent 
Cannabis users; high users, sporadic users, and increas-
ing users. Sporadic and high usage groups showed far 
lower obesity  rates than low  users (AOR for  sporadic  
use = 0.2 and for high use = 0.1). In contrast, the sub-
jects on the increasing usage trajectory showed in-
creased obesity rates relative to low users 
(AOR = 1.6). This was the only report identified in 
the literature of an AOR for obesity >1. 
The mean AOR across data points from these studies 
was 0.68. The effect size was large (Hedges’ g with 
bias correction = 1.074, Ncannabis = 18, and Ncontrol = 6),58 
and the mean odds ratio of users across all studies 
and usage groups (mean OR = 0.68) suggests obesity 
rates are reduced enough in users to provide significant 
health benefits. Several tests were used to evaluate het-
erogeneity of the AOR data. The 95% confidence in-
terval of the AOR data of users did not include 1 
(95% CI = 0.53–0.84). The Wilcoxon rank-sum test 
using data from the highest usage rates within each 
study or group resulted in a significant impact of Can-
nabis use on AOR (0.0025 < p < 0.005; N1 = N2 = 9, 
U = 9, 72). The v 2 test using data from all user groups 
failed to reject the null hypothesis, however 
(v 2 = 3.78, 0.1 < p < 0.05). 
A recent review cited Mittleman66 as reporting in-
creased obesity rates in Cannabis users,34 but this ap-
pears to be a misinterpretation of the data presented 
in that study. Mittleman et al.66 showed that, of pa-
tients who had suffered a myocardial infarction (MI), 
those who used Cannabis were more likely to be 
obese. This is quite different from finding that Canna-
bis users were more likely to be obese. These data could 
be interpreted instead as evidence for protection of 
nonobese Cannabis users from MI. These data were 
therefore not included in the analysis. 
Overall, 17 studies have presented data from 19 data 
sets on the relationship between Cannabis use and body 
mass or rates of obesity. These studies provided a total of 
36 individual data points for BMI or AOR, and 35 of 
these show BMI or obesity values for Cannabis users 
that are less than values for nonusers. Both the BMI 
data and the AOR data show lower BMI or rates of over-
weight or obesity in Cannabis users (BMI: paired t-test 
p < 0.001; AOR 95% CI = 0.53–0.84) (Tables 1 and 2). 
Both data sets show strong effect sizes (Hedges g: 
BMI = 1.16 and obesity AOR = 1.07).58 
Further evidence comes from the recent observation 
that legalization of medical Cannabis at the state level is 
associated with a rapid decrease in statewide obesity 
rates,67 and that obese rats exposed to Cannabis ex-
tract show reduced rates of weight gain.68 Indeed, 
the inverse relationship between obesity and Canna-
bis use in humans led Le Foll et al.69 to propose Can-
nabis as a possible therapeutic option for weight loss, 
and evidence accumulated since then has only 
strengthened the association. 
Caloric intake data 
Interestingly, frequent Cannabis users appear to have 
increased caloric intake relative to nonusers, despite 
lower BMI. 
Rodondi et al.70 found that users who had consumed 
Cannabis for more than 1800 days over 15 years con-
sumed on average 619 more calories/day than nonus-
ers, yet showed no difference in BMI (Table 1). 
Smit and Crespo71 reported lower BMI in users 
(24.7 – 0.3) than nonusers (26.6 – 0.1), despite users 
consuming 564 additional calories relative to nonusers 
( p < 0.0001). 
Ngueta et al.72 also observed higher values for caloric 
intake in Cannabis users relative to nonusers; although 
this was not statistically significant (2375 kcal/day vs. 
2210 kcal/day; p = 0.07). Despite this, the users had 
lower BMI ( p < 0.001). 
Foltin et al.73 found Cannabis users to have a sub-
stantial increase (1095 kcal/day) in daily caloric intake, 
although this was a short-term experimental study 
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rather than a comparison between free-range Canna-
bis users and nonusers. 
Across these studies, on average, Cannabis users 
consumed an additional 834 kcal/day relative to nonus-
ers. As BMI of Cannabis users is lower than nonusers, 
this suggests that Cannabis users must have increased 
metabolic rates. 
Previous explanations proposed for lower 
BMI in Cannabis users 
Any theory explaining mechanistically how Cannabis 
use causes reduced BMI must consider the paradoxical 
increase in caloric intake of users. To date, such a the-
ory is lacking and the interactions between Cannabis 
use and obesity are not well understood.34 
Proposed explanations for reduced BMI in Cannabis 
users include substitution of Cannabis for food in brain 
reward pathways.61 Pagotto et al.74 suggested that the 
sedative effects of high doses of Cannabis could reduce 
food consumption, but Rajavashisth et al.60 observed 
detectable effects on BMI at usage rates of four times 
or less per month (25% of nonusers were obese, 
whereas 16% of people who used Cannabis one to 
four times/month were obese, p < 0.001). Sabia et al.67 
suggested that reduced alcohol use by younger users, 
and increased physical activity of older users upon ini-
tiating medical marijuana use, may be responsible for 
the observed decrease in BMI.  
While all of these factors may contribute, reduced 
BMI in conjunction with increased caloric intake 
strongly suggests that the mechanisms causing the ob-
served decreases in BMI or obesity rates of Cannabis 
users must include differences in metabolism, not 
changes in caloric intake or activity-related energy ex-
penditures alone. These explanations obviously do not 
account for increased caloric intake in Cannabis users. 
Le Foll et al.69 suggested that D9-tetrahydrocannabinol 
(THC) may act as a functional antagonist in high eCB 
tone, as occurs in obesity, reducing BMI in Cannabis 
users.69 This is essentially what we are proposing, but 
does not address the mechanism involved. 
Theoretical explanation for the decreased 
BMI of Cannabis users 
There are currently no proposed mechanisms for re-
duced BMI in Cannabis users that account for their 
FIG. 3. The impact of Cannabis use on the endocannabinoid system of people consuming a diet 
characterized by an elevated omega-6/omega-3 ratio. Acute effects of Cannabis and/or THC consumption 
include hypothermia and hyperphagia, leading to increased energy intake and storage. However, Cannabis 
use also causes long-term downregulation of CB1R, leading to decreased CB1R activity, as shown in the insert 
on the lower right, in which each spike follows acute Cannabis ingestion, while the overall activity level 
remains depressed. Decreased CB1R activity results in a decrease in energy assimilation and an increase in 
metabolic rates, resulting in a decline in body mass despite stimulation of CB1R during acute exposure. 
THC, D9-tetrahydrocannabinol. 
Clark, et al.; Cannabis and Cannabinoid Research 2018, 3.1 266 
http://online.liebertpub.com/doi/10.1089/can.2018.0045 
increased caloric intake. The central role of CB1R in  
appetite, energy intake, energy conservation, and diet-
induced obesity, and the hyperphagia and hypothermia 
resulting from acute stimulation of CB1R by  THC,  
makes CB1R a prime suspect for a causative role in the 
effects of Cannabis use on BMI.22–24,27–32,41–46,74,75 
A novel theory for the impact of Cannabis use on 
BMI involving changes in CB1R expression is proposed 
here (Fig. 3). This multipart theory includes the follow-
ing components: 
1. A diet characterized by an elevated ratio of 
omega-6/omega-3 fatty acids, typical of processed 
foods high in grains and soybean oil, and animals 
reared on these foods, results in elevated levels of 
the eCB signals AEA and 2-AG. 
The evidence is well established.19,22,23,25,28,49 
2. Elevated AEA and 2-AG act to overstimulate the 
eCB receptor CB1R, resulting in increased appe-
tite and palatability of food, increased rates of en-
ergy uptake and storage, and decreased resting 
metabolic rates. These result in dysregulation of 
glucose and lipid metabolism, metabolic syn-
drome, and obesity. 
The evidence is well established and is summa-
rized in multiple recent reviews, for example, 
see Refs.19,22,23,27–29 
3. Decreased CB1R activity reduces obesity and 
metabolic disruption. Strong evidence in sup-
port of this statement is provided in laboratory 
experiments and clinical trials using CB1R an-
tagonists, including rimonabant, AM6545, and 
URB447. 
Rimonabant caused weight loss, improved 
lipid profiles, improved glucose sensitivity, and 
reduced atherosclerosis in animals and human 
subjects.55,56,76 Unfortunately, it also caused se-
vere psychiatric side effects in clinical trials, in-
cluding depressive disorders, dizziness, nausea, 
and anxiety, and trials were therefore terminat-
ed.55,56,76 The peripherally restricted CB1R antag-
onists, AM6545 and URB447, decreased sham 
feeding of fatty foods and hyperphagia in rats, re-
ducing caloric intake.45,46 
4. Cannabis use causes downregulation of CB1R, 
reducing the impact of enhanced AEA and 2-AG 
production arising from an elevated dietary omega-
6/omega-3 ratio. 
Multiple studies show that CB1R is downregu-
lated during Cannabis tolerance, and the receptor 
remains downregulated for about 3–4 weeks after 
57,77–80cessation of use. 
Observations supporting this theory 
There is abundant evidence that rates of obesity and 
metabolic syndrome are increasing with changes in 
diet.1–4,6,13,14,16,33,81 
There is abundant evidence that these dietary changes 
include a shift to a high omega-6/omega-3 ratio.13–19,22,23 
There is abundant evidence that an elevated omega-
6/omega-3 ratio increases eCB tone by increasing AEA 
and 2-AG levels, overstimulating CB1R.
15,18,19,22–30,55,82 
There is abundant evidence that overstimu-
lation of CB1R increases adiposity and leads to 
metabolic syndrome, contributing to chronic dis-
10,18,19,22,23,25,27–32,41–46,54,55,82 eases. 
There is abundant evidence that reduced CB1R 
activity results in weight loss. eCBs are strongly 
involved in energy expenditures, increasing caloric 
intake, and reducing whole-body energy metabo-
lism.24,28,31,32,41–46,48,50,52,55 The CB1R antagonist 
rimonabant increases O2 consumption and resting en-
ergy expenditures in both rats and in humans. In rats, it 
increases O2 consumption by 18% at a dosage of 3 mg/ 
kg and 49% at 10 mg/kg after 3 h of exposure. In hu-
mans, it increases resting energy expenditures of over-
weight or obese subjects and leads to weight loss.55,56 
Similarly, the peripherally restricted CB1R antagonists 
URB447 and AM6545 reduce energy intake. URB447 
reduced rates of fat ingestion in sham-feeding rats, 
while AM6545 attenuated diet-induced hyperphagia.43,44 
There is abundant evidence that exposure  to  
Cannabis and/or THC results in downregulation 
of CB1R. Regular Cannabis use is associated with de-
sensitization and downregulation of CB1R, and CB1R 
levels remain depressed for 3–4 weeks following cessa-
57,77–80 Because CB1R plays  a  major  role  tion of use. 
in assimilation, storage, and conservation of energy, 
this downregulation results in decreased eCB tone. 
According to the theory put forth in this article, 
acute exposure results in the ‘‘munchies,’’ stimulating 
appetite and energy consumption and causes hypo-
thermia as metabolic rates decrease. However, rapid 
downregulation of CB1R following consumption 
leads to long-term effects that more than offset the 
short-term increase in energy stores that follow acute 
exposures. 
The current meta-analysis provides strong evidence 
that Cannabis use, and/or exposure to THC, results 
in reduced BMI (Tables 1 and 2 and Fig. 2). 
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Predictions arising from theory 
Prediction 1: Cannabis users lose additional weight dur-
ing abstinence. BMI is reduced in Cannabis users, 
and should decrease even more when users stop 
using Cannabis, because CB1R remains  downregu-
lated for several weeks following chronic Cannabis 
consumption.57,77–80 Recently abstinent users would 
show reduced appetite and increased metabolic rates 
during this time. However, they will no longer experi-
ence short-term stimulation of appetite, energy intake 
and storage, and reduced metabolic rates during each 
episode of acute Cannabis consumption. Therefore, 
weight loss will increase as energy intake and storage 
remain depressed, and metabolism stimulated, until 
CB1R returns to pre-Cannabis use levels. 
This prediction is supported, as weight loss during 
withdrawal from Cannabis is one of the seven symp-
toms of Cannabis withdrawal listed in DSM-V.83,84 
Prediction 2: moderate Cannabis use reduces the inci-
dence of disorders associated with obesity and meta-
bolic syndrome. Because Cannabis use is associated 
with reduced rates of obesity, it should also reduce 
rates of obesity-related diseases in users. There is some 
evidence for this, but results are inconsistent. 
Multiple studies, including several using the National 
Health and Nutrition Examination Survey (NHANES) 
database, have reported in Cannabis users reduced 
rates of DM, insulin insensitivity, or metabolic syndrome 
in fully adjusted models, including age.60,64,72,85–87 Yankey 
et al.88 also reported decreased DM rates (AOR 0.42) 
that did not reach statistical significance (95% CI = 0.13– 
1.36). In contrast, analysis of data from the CARDIA 
data set failed to detect this relationship.89 Danielsson 
et al.62 found decreased rates of DM in Cannabis users 
in a dataset of Swedish conscripts (OR 0.74), but unlike 
the studies from the NHANES data set, this effect was no 
longer significant after adjustment for age (AOR 0.74 be-
fore adjustment, 0.94 after adjustment). 
Cannabinoids have potent anticancer proper-
ties,15,90 and a recent review concluded that Cannabis 
users may have lower rates of cancer than nonusers. 91 
Multiple laboratory studies have shown that THC 
slows or reverses the progression of Alzheimer’s dis-
ease, although clinical trials are lacking.92–96 In con-
trast, evidence available to date does not support 
reduced rates of cardiovascular disease in Cannabis 
users,97 although more studies are clearly warranted 
on this topic. 
Prediction 3: the occurrence and magnitude of meta-
bolic benefits from Cannabis use depend on the dietary 
omega-6/omega-3 ratio. The impact of diet on the  
eCB system is predicted to differ among populations be-
cause different populations have different diets, consum-
ing different proportions of green vegetables, industrially 
produced animals, oceanic fishes, and processed foods. 
According to the theory established in the current 
article, populations with diets characterized by a high 
omega-6/omega-3 ratio will see significantly larger 
health improvements from Cannabis use than those 
eating diets with more moderate ratios of omega-6/ 
omega-3 FAs. This may explain some of the inconsis-
tencies in the data on the metabolic impact of Cannabis 
use; for example, Cannabis use by Swedish popula-
tions62,98 may not have the same health impacts as 
Cannabis use by Americans due to the different dietary 
backgrounds and obesity rates of these populations. 
Cannabis use in the United States appears to provide 
significant public health benefits due to partial or com-
plete reversal of the metabolic dysregulation caused by 
the strongly elevated omega-6/omega-3 ratio of the 
American diet. 
Prediction 4: Cannabis use and omega-3 supplements 
have similar impacts on health. Both omega-3 FAs 
and Cannabis reduce eCB tone, through distinct 
mechanisms. Omega-3 FAs compete with omega-6 
FAs for the enzymes synthesizing AEA and 2-AG 
from omega-6 FAs, and omega-3 supplements thereby 
reduce the synthesis of AEA and 2-AG and reduce 
stimulation of CB1R.
13,21,22,25,49 
Cannabis use causes downregulation of CB1R,
57,77–80 
reducing the sensitivity to elevated AEA and 2-AG. 
Thus, the theory predicts that omega-3 FA supplements 
and Cannabis use should have similar positive health 
impacts in the context of metabolic dysregulation from 
a diet with an elevated omega-6/omega-3 ratio. How-
ever, it is likely that the overlap is not complete as the 
precursor of AEA and 2-AG, arachidonic acid,22 also 
gives rise to proinflammatory leukotrienes and pros-
taglandins,99 an effect that might not be impacted 
by decreased CB1R tone.  
Prediction 5: the combination of omega-3 sup-
plements and Cannabis or cannabinoids could be a 
particularly potent treatment for obesity, metabolic 
syndrome, cancer, and so on. Reducing AEA and 
2-AG synthesis with omega-3 supplements, and at 
the  same time reducing  CB1R density with Cannabis 
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FIG. 4. Proposed weight loss therapy based on theory. Daily omega-3 fatty acid supplements (especially 
with decreased dietary omega-6 fatty acids) will reduce levels of AEA and 2-AG, reducing stimulation of CB1R, 
while weekly Cannabis use will cause downregulation of CB1R. Thus, this approach will act to both reduce 
levels of the endocannabinoid signals and reduce the sensitivity of target cells to those signals. The net 
effect is predicted to be a more potent weight loss strategy than diet alone. 
use, should reduce BMI and cardiometabolic risk factors 
more than either option alone (Fig. 4). Note that, be-
cause CB1R remains downregulated for some time fol-
lowing use, weekly Cannabis use may be sufficient to 
observe significant weight loss and metabolic benefits. 
Conclusions/Summary 
Obesity and elevated BMI are strongly associated with 
disease states, and there are significant financial and 
public health incentives to develop effective interven-
tions to help people achieve a healthy body mass. Phar-
macological weight loss therapy is recommended when 
BMI is ‡27 in the presence of obesity-related risk fac-
tors and >30 in the absence of such risk factors.53 
The development of pharmacological weight loss 
methods has been problematic, Rimonabant, a CB1R 
antagonist, showed promise in laboratory studies, but 
clinical trials were discontinued due to serious psychi-
atric side effects,53,54 although ongoing studies suggest 
that peripherally restricted CB1R antagonists  may  
provide therapeutic benefits in obesity without such 
psychiatric side effects.43–46 
Surgical methods such as the lap band or bariatric 
surgeries are frequently used when dietary or pharma-
ceutical interventions do not work, and any surgical pro-
cedure entails risk and recovery. Surgical procedures are 
also expensive. Therefore, relatively safe and inexpensive 
methods to reduce obesity and prevent or reduce some 
of the most deadly and costly chronic diseases character-
izing western societies merit serious consideration. 
For many patients, Cannabis may be a better option 
for weight loss than surgery or pharmaceuticals. How-
ever, patients with preexisting cardiovascular condi-
tions or prior MIs should avoid cannabinoids or use 
them with caution.66,91,100 
A number of states and the federal government have 
legalized Cannabis products containing cannabidiol, 
but continue to ban legal access to products containing 
THC. Evidence available at this time suggests that it is 
ingestion of THC that is responsible for downregula-
tion of CB1R, and therefore, for reduced obesity rates 
of Cannabis users. Our theory suggests that the psycho-
active effects of CB1R stimulation with THC may be a 
necessary accompaniment to Cannabis-induced weight 
loss, because downregulation of CB1R is required for 
reduced BMI, and it is not yet clear whether microdos-
ing will cause downregulation. However, weekly or bi-
weekly Cannabis use may be sufficient as significant 
decreases in BMI are observed at weekly usage rates.60 
Medical marijuana use is increasing, leading to de-
creased use of multiple classes of pharmaceuticals. 
Patients cite improved symptom management, fewer 
adverse side effects, and milder withdrawal symptoms 
as reasons for switching from pharmaceuticals to 
medical Cannabis.101–108 Once patients become aware 
that the side effects of medical Cannabis may include 
weight loss and reduced risk of obesity-associated med-
ical conditions, this shift toward medical Cannabis is 
likely to accelerate. Available data suggest that this 
will save many lives, not only from reduced rates of 
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obesity-related chronic illnesses but also from reduced 
deaths from pharmaceutical overdose.91,105,109 
This study provides a theoretical platform to inform 
future studies on the correlations between Cannabis 
use and cardiometabolic risk factors. This theory may 
explain inconsistencies among studies on the impact 
of Cannabis use on metabolic dysregulation, as differ-
ent populations have different diets. For example, epi-
demiological studies of the impact of Cannabis use by 
cohorts of Swedish conscripts may reveal different re-
sults than epidemiological studies in the United States, 
due to different levels of obesity in the two countries. 
Cerdá et al.98 found that early, heavy Cannabis use 
among Swedish conscripts is associated with increased 
mortality later in life. In contrast, Clark91 concluded 
that Cannabis use is associated with a substantial de-
crease in the premature death rate in the United States, 
as it is associated with reduced rates of cancer, DM, 
pharmaceutical use, deaths from brain trauma, and 
may slow the progression of Alzheimer’s and other 
neurodegenerative diseases. 
The strong evidence for interactions between the di-
etary omega-6/omega-3 ratio, obesity, and Cannabis 
use suggests that the balance between positive and neg-
ative health impacts of Cannabis use will differ in 
Swedish and United States populations. Evidence sug-
gests that, in the United States, many people may actu-
ally achieve net health benefits from moderate 
Cannabis use, due to reduced risk of obesity and asso-
ciated diseases. 
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98. Cerdá M, Moffitt TE, Meier MH, et al. Persistent cannabis dependence 
and alcohol dependence represent risks for midlife economic and 
social problems: a longitudinal cohort study. Clin Psychol Sci. 2016;4: 
1028–1046. 
99. Meng H, Liu Y, Lai L. Diverse ways of perturbing the human arachidonic 
acid metabolic network to control inflammation. Acc Chem Res. 2015;48: 
2242–2250. 
100. Franz CA, Frishman WH. Marijuana use and cardiovascular disease. 
Cardiol Rev. 2016;24:158–162. 
101. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with 
decreased opiate medication use in a retrospective cross-sectional sur-
vey of patients with chronic pain. J Pain. 2016;17:739–744. 
102. Bradford AC, Bradford WD. Medical marijuana laws reduce prescription 
medication use in medicare part D. Health Aff (Millwood). 2016;35: 
1230–1236. 
103. Bradford AC, Bradford WD, Abraham A, et al. Association between US 
state medical cannabis laws and opioid prescribing in the Medicare Part 
D population. JAMA Intern Med. 2018;178:667–672. 
104. Haroutounian S, Ratz Y, Ginosar Y, et al. The effect of medicinal Cannabis 
on pain and quality-of-life outcomes in chronic pain: a prospective 
open-label study. Clin J Pain. 2016;32:1036–1043. 
105. Bachhuber MA, Saloner B, Cunningham CO, et al. Medical cannabis laws 
and opioid analgesic overdose mortality in the United States, 1999– 
2010. JAMA Intern Med. 2014;174:1668–1673. 
106. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for 
prescription opioids and other substances: a survey of authorized 
medical cannabis patients. Int J Drug Policy. 2017;42:30–35. 
107. Lucas P, Reiman A, Earleywine M, et al. Cannabis as a substitute for 
alcohol and other drugs: a dispensary-based survey of substitution 
effect in Canadian medical cannabis patients. Addict Res Theory. 2013; 
21:435–442. 
108. Wen H, Hockenberry JM. Association of medical and adult-use marijuana 
laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med. 
2018;178:673–679. 
109. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, 
United States, 2010. JAMA. 2013;309:657–659. 
110. Gerberich SG, Sidney S, Braun BL, et al. Marijuana use and injury events 
resulting in hospitalization. Ann Epidemiol. 2003;13:230–237. 
111. Le Strat Y, Le Foll B. Obesity and cannabis use: results from 2 
representative national surveys. Am J Epidemiol. 2011;174:929–933. 
112. Barry D, Petry NM. Associations between body mass index and 
substance use disorders differ by gender: results from the National 
Epidemiologic Survey on Alcohol and Related Conditions. Addict Behav. 
2009;34:51–60. 
Cite this article as: Clark TM, Jones JM, Hall AG, Tabner SA, Kmiec RL 
(2018) Theoretical explanation for reduced body mass index and 
obesity rates in Cannabis users, Cannabis and Cannabinoid Research 
3:1, 259–271, DOI: 10.1089/can.2018.0045. 
Abbreviations Used 
2-AG ¼ 2-arachidonoylglycerol 
AEA ¼ anandamide; N-arachidonoylethanolamide 
ALA ¼ a-linolenic acid 
AOR ¼ adjusted odds ratio 
BMI ¼ body mass index 
CB1R ¼ Cannabinoid receptor 1 
CB2R ¼ Cannabinoid receptor 2 
CNS ¼ central nervous system 
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